Interleukin (IL)-33 can function both as a conventional cytokine and as a nuclear factor regulating gene transcription. IL-33 expression is strongly upregulated in the nucleus of keratinocytes and serum of patients with psoriasis. However, the role of IL-33 in psoriasis is unclear, and IL-33 expression in the lesional psoriatic skin after conventional systemic treatments has not been investigated. In this study, we aimed to compare IL-33 mRNA in patients' lesional skin samples and IL-33 protein expression in patients' serum before and after treatment with methotrexate (MTX) and narrowband ultraviolet B (NB-UVB). IL-33 mRNA levels in lesional skin and IL-33 protein levels in serum were downregulated after treatment with MTX. Results revealed a significant decrease in IL-33 protein expression (P = 0.028). IL-33 expression increased after NB-UVB treatment. IL-33 production is associated with inflammatory skin in psoriasis, possibly through its cytokine function. However, high expression of IL-33 after NB-UVB treatment suggests the occurrence of unknown functions to alleviate psoriatic lesions without IL-33 involvement.
INTRODUCTION
Interleukin (IL)-33 is considered a novel "alarmin" that is released upon cell injury or damage. 1 It was first described as a cytokine that mediates the T-helper (Th)2 inflammatory pathway. 2 IL-33 is constitutively expressed in tissues exposed to the environment, where the nuclei of endothelial and epithelial cells, including keratinocytes, are its major sources. 1, expression has also been reported in psoriatic skin lesions, which is a Th1/Th17-mediated immunological skin disease. 4, 5 IL-33 levels are significantly increased in affected skin in patients with psoriasis, as compared with those in healthy skin and in patients with other inflammatory skin disorders. [4] [5] [6] Suttle et al. 7 have suggested that IL-33 is released from epidermal keratinocytes after slightly damaging the skin surface in psoriasis. Additionally, recent studies have demonstrated that serum IL-33 levels are increased in patients with psoriasis, indicating that IL-33 may represent a novel marker of the disease. Anti-tumor necrosis factor (TNF)-a treatment could downregulate increased IL-33 expression in psoriatic lesions. Balato et al. 9 demonstrated that IL-33 levels were significantly decreased after treatment with adalimumab in patients with psoriasis. Vageli et al. 10 reported that the levels of IL-33 mRNA were downregulated after treatment with etanercept or infliximab. Mitsui et al. 8 recently demonstrated that serum IL-33 levels were correlated with serum TNF-a levels, and were significantly decreased after treatment with TNF-a agents.
In the present study, we analyzed the effects of two different modalities, methotrexate (MTX) and narrowband ultraviolet B (NB-UVB) radiation, on IL-33 mRNA and protein levels in psoriatic plaques and serum.
CASE REPORT Methods
Fourteen patients visiting the outpatient clinics of the Departments of Dermatology of Thammasat University Hospital were enrolled in this study.
Patients (aged ≥18 years) who had moderate to severe plaque-type psoriasis, as assessed using the Psoriasis Area and Severity Index (PASI), were included in this study. All patients were asked to discontinue any systemic treatments and phototherapy for at least 4 weeks, and topical therapies for at least 2 weeks before entering the study. The exclusion criteria were as follows: patients with contraindications of NB-UVB or MTX, psoriatic arthritis, IL-33-associated disease (e.g. rheumatoid arthritis, asthma) and immunocompromised conditions. This study was approved by the human research ethics committee of Thammasat University No. 1 (certificate of approval, 032/2559), and all patients gave their written informed consent.
The patients were divided into two treatment groups (group M, MTX-treated patients; group N, NB-UVB-treated patients) depending on each patient's indication.
Patients received MTX p.o. (7.5-20 mg) once a week or NB-UVB irradiation three sessions per week. A starting dose of 200-300 mJ/cm 2 was administrated to the patients using a
Waldmann UV5002 cabinet (Villingen-Schwenningen, Germany). Dose increments were then continued by 10-20 mJ/cm 2 in subsequent sessions, and increased accordingly depending on clinical response and skin tolerance until clearance of disease, defined as 75% reduction in the PASI score (PASI-75) or completion of 12 weeks of treatment. Three milliliters of blood and 4-mm punch skin biopsies from mature lesions were collected from 14 patients with psoriasis and analyzed before (day 0) and after (PASI-75 or the end of 12 weeks) treatment with MTX or NB-UVB.
Measurement of IL-33 by enzyme-linked immunosorbent assay (ELISA)
The concentration of IL-33 in serum was measured using the Human IL-33 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Quantitative polymerase chain reaction
Total cellular RNA was isolated and purified using the RNeasy â Mini Kit (Qiagen, Hilden, Germany). cDNA was synthesized using the ImProm-II TM Reverse Transcription System (Promega, Madison, WI, USA) according to the manufacturer's instructions. Gene analysis using TaqMan assay for human IL-33 (Hs00369211_m1) and the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was obtained from Applied Biosystems (ThermoFisher Scientific, Waltham, MA, USA). Reaction mixtures (20 lL) were placed in a C1000 Touch TM thermal cycler BIO-RAD CFX96 TM Real-Time System (Bio-Rad, Hercules, CA, USA).
Statistical analysis
The results are presented as percentages of qualitative data, median and interquartile range (IQR) for quantitative data. The equivalent non-parametric test, Wilcoxon rank sum test, was used to evaluate changes in IL-33 mRNA and serum IL-33 levels, as well as in PASI scores, before and after treatment. P < 0.05 was considered significant; all analyses were performed using STATA/ SE version 13 software (StataCorp, College Station, TX, USA).
RESULTS
Baseline characteristics of the patients are demonstrated in Table 1 . In all patients, improvement with 75% reduction in PASI score was achieved after treatment (Table 2) ; the median (IQR) PASI score was significantly reduced from 20.85 (12.95-25.05) at baseline to 3.5 (2.8-4.8) at the end of treatment with MTX (P = 0.012) and from 15.2 (14.5-16) to 1.75 (1.5-2.4) after treatment with NB-UVB irradiation (P = 0.027).
IL-33 mRNA levels in lesional skin samples were detectable in all patients. After MTX therapy, the median IL-33 mRNA level decreased from 1.77 (0.1-4.79) to 0 (0-2.32) after treatment (P = 0.612). In contrast, the median (IQR) IL-33 mRNA level increased from 0.56 (0.19-1) to 2.27 (1.19-10.07) after NB-UVB irradiation (P = 0.686, Fig. 1a) .
The serum levels of IL-33 were detectable in 14 patients. In the M group, the median (IQR) was significantly decreased from 81.11 (50.89-190.45) before treatment to 9.81 (0-114.89; P = 0.028) after treatment. In contrast, the median IL-33 serum level increased from 59.41 (39.91-87.29) to 100.01 (40.11-147.64) after treatment with NB-UVB (P = 0.109, Fig. 1b) . The change in serum IL-33 levels was consistent with those of the corresponding mRNA levels in both the M and N groups.
DISCUSSION
In this study, we demonstrated, for the first time, that IL-33 mRNA in psoriatic lesional skin and IL-33 protein in serum were expressed before and after treatment with MTX or NB-UVB phototherapy. After therapy, the expression levels of IL-33 mRNA and protein were decreased in patients with psoriasis who received MTX, while these levels were increased after treatment with NB-UVB irradiation. On the basis of these results, we speculate that IL-33 is not a key mediator associated with pathogenesis of psoriasis. The reduction in IL-33 mRNA and protein after treatment with MTX may be attributable to its antiproliferative effect. Proinflammatory cytokines such as TNF-a, c-interferon and IL-17 play crucial roles in the development of psoriasis, 11 and are involved in the production of IL-33 in keratinocytes. 4, 6, 9, 12 The suppression of these pro-inflammatory cytokines by MTX may explain the reduced levels of IL-33 expression observed in our study in the M group. Furthermore, consistent with our results, IL-33 mRNA and protein levels were found to be reduced after treatment with TNF-a inhibitors in patients with plaque psoriasis. [8] [9] [10] These results support the role of IL-33 as an extracellular cytokine that induces inflammation. 13 The results from the NB-UVB-treated group were contradictory to those from the MTX-treated group. Although not significant, the lesional skin mRNA and serum protein levels of IL-33 were upregulated after NB-UVB phototherapy in patients with psoriasis. These results were consistent with the findings of Byrne et al., 14 and to those of Meephansan et al., 15 who reported elevated IL-33 expression in human skin samples ex vivo and normal human epidermal keratinocytes until 72 h after UV-B exposure. However, the current study demonstrated an upregulation of IL-33 expression in patients with psoriasis at 48 h after clinical improvement with the irradiation. Upregulation of IL-33 levels may be a direct effect of UV-B radiation on the skin but not involved in pathogenesis of psoriasis. In summary, the exact function of this new cytokine in psoriasis remains ambiguous. However, the present data indicate that the levels of IL-33 are altered in plaque-type psoriasis through systemic therapies, leading to improvement of disease. Nevertheless, the results obtained for MTX therapy and NB-UVB irradiation were contradictory. Our findings imply that the production of IL-33 is associated with skin inflammation in psoriasis, and the discrepancies between the results should be clarified in future studies. (a) (b) Figure 1 . mRNA level in (a) lesional skin and (b) protein level (pg/mL) in serum of interleukin (IL)-33 in psoriatic patients before and after treatment with methotrexate (MTX) and narrowband ultraviolet-B radiation (NB-UVB). GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
